摘要
Abstract
Objective To investigate the effects of bevacizumab combined with oxaliplatin on tumor marker levels,immune response,and disease outcomes in colorectal cancer,aiming to provide scientific guidance for clinical management.Methods Total 68 colorectal cancer patients treated at the First Affil-iated Hospital of Xinxiang Medical University from January 2022 to December 2023 were enrolled and ran-domly divided into a control group and an observation group,with 34 cases in each group.The control group received oxaliplatin and capecitabine,while the observation group received additional bevacizumab.Clinical efficacy,tumor marker levels,immune function indicators,and adverse reactions were compared be-tween the two groups.Results The total effective rate in the observation group was significantly higher than that in the control group(P＜0.05).Before treatment,tumor marker levels showed no significant difference between the two groups(P＞0.05).After treatment,tumor marker levels decreased in both groups,with lower levels in the observation group(P＜0.05).There was no significant difference in im-mune function indexes between the two groups before treatment(P＞0.05).After treatment,levels of IgA,IgM,IgG,CD3+,and CD4+increased in both groups,with higher levels in the observation group(P＜0.05).No significant difference in adverse reaction rates was observed between the two groups(P＞0.05).Conclusion Bevacizumab combined with oxaliplatin can significantly reduce tumor marker levels,enhance immune function,and improve prognosis in patients with colorectal cancer,making it worthy of clinical application.关键词
结直肠癌/贝伐珠单抗/奥沙利铂/免疫功能/预后Key words
Colorectal cancer/Bevacizumab/Oxaliplatin/Immune function/Prognosis
